RxDoctor Payments Data

Jacob Leger, MD

Family Medicine · Lake Charles, LANPI 1346701422

Payments from drug & device makers

$1,012in general payments, 2019–2025

Across 48 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$240
  • Harmony Biosciences LLC$159
  • Astellas Pharma US Inc$122
  • Dexcom, Inc.$77
  • Exact Sciences$57
  • Lilly USA, LLC$41
  • plus $317 from 12 others

What the payments were for

  • Food & beverage$92291%
  • Education$909%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,012 in reported general payments places this provider in the 55th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$7,615
Medicare patients
53
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide77$108,792
JardianceEmpagliflozin87$96,442
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$52,303
VraylarCariprazine Hcl28$44,403
EliquisApixaban33$40,412
FarxigaDapagliflozin Propanediol39$31,314
OzempicSemaglutide21$29,590
LinzessLinaclotide34$22,038
EntrestoSacubitril/Valsartan22$19,713
KerendiaFinerenone11$9,508
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl29$8,306
BelsomraSuvorexant17$7,333
Gabapentin212$3,624
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,878
Diclofenac Sodium50$1,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$41$108,79277 claims
AbbVieVraylar, Linzess$240$66,44162 claims
AstraZenecaFarxiga$31$31,31439 claims
Novo NordiskOzempic$32$29,59021 claims
BayerKerendia$14$9,50811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →